After nearly two decades of sluggish growth and many R&D disappointments, the stars are aligning for a new wave of breakthrough innovations for the treatment of central nervous system (CNS) disorders.
Our research explores the enablers of R&D breakthroughs in the treatment of these conditions and examines trends in how the pharmaceutical industry is embracing this momentous opportunity and identifies critical success factors for CNS innovators.